SSY GROUP (02005): The hydrochloride of Diltiazem Tablets (30mg) has been approved by the National Medical Products Administration and has passed the consistency evaluation of quality and efficacy for generic drugs.

SSY GROUP (02005) announced that the hydrochloride Diltiazem tablets (30mg) have been approved by the National Medical Products Administration of China to pass the consistency evaluation of quality and efficacy for generic drugs, making it the third domestic company to receive such approval. The hydrochloride Diltiazem tablets are mainly used for the treatment of angina pectoris and mild to moderate primary hypertension. The Group has obtained the drug production registration certificate for injectable hydrochloride Diltiazem. With the approval of the consistency evaluation for the tablets, hospitals can implement in-house emergency injections and outpatient oral continuation treatment, forming a product combination for intensive care units (ICU), cardiology, and emergency departments, thereby strengthening the Group's product capabilities in chronic diseases of the cardiovascular and cerebrovascular systems and critical care fields.